Work Here?
Overview
Nusano produces and supplies high-purity, cGMP-grade radioisotopes for medical, industrial, and commercial use. It operates a proprietary production platform that combines a high-current ion source with a linear accelerator to create more than 40 different radioisotopes, capable of producing up to 12 isotopes simultaneously. The system can switch between isotopes in minutes, enabling versatile supply for drugmakers, hospitals, clinics, and industrial partners. This differs from traditional reactor-based methods by offering rapid isotope changes, high flexibility, and scalable production, backed by supply agreements and beam-time reservations. Nusano aims to commercialize its initial products, lutetium-177 n.c.a. and actinium-225, starting in 2025, and to become a reliable, diversified isotope supplier for the healthcare and industrial sectors.
About Nusano
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$125M
Headquarters
Santa Clarita, California
Founded
2013
People at Nusano
People at Nusano who can refer or advise you
Simplify's Take
What believers are saying
- Multi-year supply agreements with Cellectar and Clarity secure critical radioisotope demand.
- Copper-64 capacity exceeds 18,000 patient doses daily, supporting late-stage trials.
- Strategic location near SLC airport enables rapid global isotope delivery for patients.
What critics are saying
- Novartis and GSK scaling reactor networks undercut Nusano's 2025 launch with lower costs.
- FDA delays for Ac-225 validation could postpone commercial release beyond H2 2025.
- Single-facility model faces existential risk from regional earthquake without redundant production site.
What makes Nusano unique
- Nusano's proprietary ion source enables switching isotopes in minutes instead of months.
- The facility produces 40+ radioisotopes with 12 simultaneous beam lines.
- Nusano's accelerator-based method offers cost-effective mass production of copper-64 and other isotopes.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$125M
Above
Industry Average
Funded Over
2 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 4%2 year growth
↑ 3%Nicole Vazquez named to Utah Business women to Watch List. WEST VALLEY CITY, Utah - May 8, 2026 - Nusano's director of Logistics & Customer Service, Nicole Vazquez, has been named to Utah Business' 2026 "Women to Watch" List. The honor recognizes women making a meaningful impact where they work and "trailblazing new paths in their fields." In her role at Nusano, Vazquez leads the team responsible for building the systems and processes to manage all aspects of customer relations and order fulfillment, including supply chain, order scheduling and procurement. Describing her work to Utah Business, Vazquez remarks: "Kindness, to me, isn't a weakness. It's about listening, understanding different perspectives and responding with clarity and intention. Especially in supply chain, where things can shift in a moment, I've found that being steady, resilient and kind helps teams stay grounded and aligned even when the pressure is high." Her complete profile can be found on the Utah Business website.
Nusano receives "Best Companies to Work For" Award from Utah Business. State's top workplaces identified by employee survey data. WEST VALLEY CITY, Utah - Dec. 11, 2025 - Nusano, physics company working to transform radioisotope production and enable industries ranging from healthcare to nuclear energy, today received a Best Companies to Work For award from Utah Business. Each year, Utah Business anonymously surveys thousands of individuals to identify workplaces where employees feel engaged, recognized and appreciated. Firms rising to the top of the survey data receive a Best Companies to Work For award. "Nusano has assembled some of the most talented, forward-thinking teams in all of science and industry," said Chris Lowe, CEO of Nusano. "As we strive to make the world better, we start at home with our people. This award is special because it is based on direct feedback from our employees. We will continue investing in our teams to ensure next-generation solutions are built in Utah and delivered globally." The complete list of 2025 Best Companies to Work For honorees is available on the Utah Business website. About Nusano Headquartered in West Valley City, Utah, Nusano is a privately held physics company working to stabilize supply chains, advance American national security by reducing dependency on foreign supply, and enable once-in-a-generation innovations in fields ranging from healthcare to nuclear energy. The company is commercializing platform technologies for radioisotope production, stable isotope enrichment, and advanced separation techniques. Together, these proprietary systems and methods are poised to supply the fight against cancer, fuel the nuclear renaissance, and deliver critical minerals for the modern world. For more, visit nusano.com. * Media: Scott Larrivee, Nusano, 608-345-6629, [email protected] * Investor Relations: Joyce Allaire, LifeSci Advisors, LLC, 212-915-2569, [email protected]
Nusano receives Innovation Impact Award from BioUtah. Company's radioisotope production platform recognized for potential impact on next-generation cancer diagnostics and therapeutics. Members of the Nusano team celebrate the Innovation Impact Award at the Utah Life Sciences Summit in Salt Lake City on November 12. 2025. SALT LAKE CITY - Nov. 12, 2025 - Nusano, a physics company enabling industries ranging from healthcare to nuclear energy, today accepted the 2025 Innovation Impact Award from BioUtah at the Utah Life Sciences Summit. The award honors organizations advancing life science innovations and creating transformative technologies. "Nusano burst onto the Utah life sciences scene a few years ago and is making a tremendous impact," Kelvyn Cullimore, president and CEO of BioUtah. "Their breakthrough capabilities are attracting new investment to the area and the radioisotopes they create are poised to help transform cancer treatment options." Current supply chains for medical radioisotopes are constrained, often posing challenges to research, drug development and patient care. Nusano's role in the health care ecosystem is as a supplier of medical radioisotopes to drugmakers, hospitals and clinics. With a reliable supply of radioisotopes, these teams can then formulate treatments and next-generation pharmaceuticals needed to advance the fight against cancer. The Nusano radioisotope production platform combines time-proven technology from universities and world-class research centers with the company's patented ion source. The result is the first significant advancement in radioisotope production in decades - a production platform that is smaller, safer and more efficient than existing methods. Housed in a custom-built 190,000-square-foot facility, Nusano's linear accelerator-based platform is capable of producing more than 40 radioisotopes, more than 25 of which have applications in the rapidly developing field of radiopharmaceuticals. "Nusano is commercializing multiple platform technologies to stabilize supply chains, enable domestic production and advance American national security," said Chris Lowe, CEO of Nusano. "We are honored to be recognized by BioUtah for our contributions to Utah's life sciences community and look forward to working with our collaborators to grow Utah's economy and improve the quality of life for people around the world." About BioUtah BioUtah is an independent 501(c)(6) trade association serving Utah's life sciences industry. Its member companies reflect a broad spectrum of strengths in medical device manufacturing and services, research and testing, biotechnology, biopharmaceuticals, and diagnostics, amongst others; and are a key driver of Utah's economy and advancing healthcare. About Nusano Nusano is a privately held physics company working to stabilize supply chains, advance American national security by reducing dependency on foreign supply, and enable once-in-a-generation innovations in fields ranging from healthcare to nuclear energy. The company is commercializing platform technologies for radioisotope production, stable isotope enrichment, and advanced separation techniques. Together, these proprietary systems and methods are poised to supply the fight against cancer, fuel the nuclear renaissance, and deliver critical minerals for the modern world. For more, visit nusano.com. Nusano * Media: Scott Larrivee, Nusano, 608-345-6629, [email protected] * Investor Relations: Joyce Allaire, LifeSci Advisors, LLC, 212-915-2569, [email protected] Nov. 6, 2025 - Nusano CEO, Chris Lowe, is the featured guest on the new edition of the Healthcare Technology Report... SALT LAKE CITY - Nov. 5, 2025 - Nusano is honored to receive the 2025 Innovation Impact Award from BioUtah. The award...
BioUtah recognizes Nusano with Innovation Impact Award. SALT LAKE CITY - Nov. 5, 2025 - Nusano is honored to receive the 2025 Innovation Impact Award from BioUtah. The award recognizes organizations making an indelible mark on Utah's life sciences community. "We are proud to recognize this year's award winners," said Kelvyn Cullimore, president and CEO of BioUtah. "These honorees exemplify the innovation and dedication that define Utah's life sciences community, and their work continues to deliver transformative healthcare solutions to patients in Utah and the world over." ...Nusano has attracted some of the brightest minds in physics, chemistry, and engineering, individuals who left long-established careers in national labs, universities, and leading life-science companies. Their decision to come to Utah is bringing world-class expertise to a region that has long sought to build deeper technical capabilities in this field. The Innovation Impact Award will be officially presented to Nusano during the 2025 Mayer Brown Utah Life Sciences Summit on November 12 in downtown Salt Lake City.
WEST VALLEY CITY, Utah - May 12, 2025 - Nusano, a physics company transforming the production of radioisotopes, today announced its Chief Product Officer, Kevin Haehl, will participate in a radioisotope supply chain panel discussion at the 21st Annual PEGS (Protein & Antibody Engineering) Summit on Wednesday, May 14, 2025, in Boston.
Nusano is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Nusano
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$125M
Headquarters
Santa Clarita, California
Founded
2013
Nusano is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today